Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 179, Issue 1, Pages 98-105Publisher
WILEY
DOI: 10.1111/bjh.14826
Keywords
indolent lymphoma; IgM monoclonal gammopathy; MYD88
Categories
Funding
- Abbvie
- Celgene
- Novartis
- Amgen
- Takeda
- Sanofi
- Janssen
- Pharmacyclics, Inc.
- Ionis Pharmaceuticals
- Prothena
- Millennium
- Karyopharm
- Celgene (Institution)
- Novartis (Institution)
- Spectrum Pharmaceuticals (Institution)
- Acerta Pharma (Institution)
- Pfizer
- Jannsen
- Alnylam
- Bristol-Myers Squibb
- Celldex
- Merck
- Affimed
- Seattle Genetics
- Takeda (Institution)
- Onyx (Institution)
- Sanofi (Institution)
Ask authors/readers for more resources
The management of Waldenstrom macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing on relapsed/refractory (R/R) patients. Ibrutinib, a recently approved agent in WM demonstrated limited activity in patients with MYD88(WT) genotype. Herein, we additionally report on the activity of DRC based on the MYD88(L265P) mutation status. Of 100 WM patients evaluated between January 2007 and December 2014 who received DRC, 50 had R/R WM. The overall response rate (ORR) was 87%. The median progression-free survival (PFS) and time-tonext- therapy (TTNT) were 32 (95% confidence interval [CI]: 15-51) and 50 (95% CI: 35-60) months, respectively. In the previously untreated cohort (n = 50), the ORR was 96%, and the median PFS and TTNT were 34 months (95% CI: 23-not reached [NR]) and NR (95% CI: 37-NR), respectively. Twenty-five (86%) of 29 genotyped patients harbored MYD88 L265P. The response rates and outcomes were independent of MYD88 mutation status. Grade = 3 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, DRC is an effective and well-tolerated salvage regimen for WM. In contrast to ibrutinib, DRC offers a less expensive, fixed-duration option, with preliminary data suggesting efficacy independent of the patients' MYD88 status.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available